Related Experiment Video

Updated: Jun 7, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.3K

TKI resistance in brain metastasis: A CTLA4 state of mind

Elena Donders1, Diether Lambrechts2

  • 1Laboratory for Translational Genetics, VIB, Leuven, Belgium; Department of Human Genetics, University of Leuven (KU Leuven), Leuven, Belgium; Pneumology - Respiratory Oncology, University Hospitals Leuven (UZ Leuven), Leuven, Belgium.

Immunity
|November 13, 2024
PubMed

Insights

Lung cancer brain metastasis (LCBM) resistance to tyrosine kinase inhibitors (TKIs) is a challenge. A new study shows TKIs alter the LCBM immune environment, suggesting CTLA4 blockade can overcome this resistance.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Lung cancer brain metastasis (LCBM) poses significant clinical challenges, particularly resistance to tyrosine kinase inhibitors (TKIs).
  • Understanding the immune microenvironment in LCBM is crucial for developing effective treatment strategies.

Purpose of the Study:

  • To investigate how TKIs affect the immune microenvironment in lung cancer brain metastasis.
  • To identify potential therapeutic strategies to overcome TKI resistance in LCBM.

Main Methods:

  • Analysis of the immune landscape within lung cancer brain metastasis following TKI treatment.
  • Exploration of immune checkpoint blockade as a means to sensitize LCBM to TKIs.

Main Results:

  • Tyrosine kinase inhibitors were found to significantly reshape the immune microenvironment of lung cancer brain metastasis.
  • Specific alterations in immune cell populations and their functions were observed.

Conclusions:

  • The study highlights the intricate interplay between TKIs and the immune system in LCBM.
  • CTLA4 blockade is proposed as a promising therapeutic approach to overcome TKI resistance in this context.

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.3K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

26.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K